<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2611">
  <stage>Registered</stage>
  <submitdate>5/11/2009</submitdate>
  <approvaldate>5/11/2009</approvaldate>
  <nctid>NCT01031186</nctid>
  <trial_identification>
    <studytitle>First Time in Human Study</studytitle>
    <scientifictitle>A First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK356278 (PDE4 Inhibitor) in Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym>FTIM</trialacronym>
    <secondaryid>113324</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Depressive Disorder and Anxiety Disorders</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Anxiety</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - GSK356278
Treatment: drugs - PLACEBO

Experimental: Cohort 1, Session 1 - In Dosing Session 1, the subjects will be administered 0.5 mg GSK356278 and placebo in a fasted state.

Experimental: Cohort 1, Session 2 - In Dosing Session 2, the subjects will be administered GSK356278 (0.5 mg and 1.5 mg) and placebo in a fasted state.

Experimental: Cohort 1, Session 3 - In Dosing Session 3, the subjects will be administered GSK356278 (1.5 mg and 4 mg) and placebo in a fasted state.

Experimental: Cohort 1, Session 4 - In Dosing Session 4, the subjects will be administered GSK356278 (4 mg and 8 mg) and placebo in a fasted state.

Experimental: Cohort 1, Session 5 - In Dosing Session 5, the subjects will be administered GSK356278 8 mg and placebo in a fasted state.

Experimental: Cohort 2, Session 1 - In Dosing Session 1, the subjects will be administered 8 mg GSK356278 and placebo in a fasted state.

Experimental: Cohort 2, Session 2 - In Dosing Session 2, the subjects will be administered GSK356278 (8 mg and 16 mg) and placebo in a fasted state.

Experimental: Cohort 2, Session 3 - In Dosing Session 3, the subjects will be administered GSK356278 (16 mg and 30 mg) and placebo in a fasted state.

Experimental: Cohort 2, Session 4 - In Dosing Session 4, the subjects will be administered GSK356278 (30 mg and 50 mg) and placebo in a fasted state.

Experimental: Cohort 2, Session 5 - In Dosing Session 5, the subjects will be administered GSK356278 50 mg and placebo in a fasted state. The subjects will undergo food assessment session in Session 5 incase they experience nausea. In food assessment session, the subjects will receive a dose of GSK356278 after a standard breakfast.


Treatment: drugs: GSK356278
GSK356278

Treatment: drugs: PLACEBO
PLACEBO

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess safety and tolerability of single escalating oral doses of GSK356278 in healthy male volunteers</outcome>
      <timepoint>72 hours</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To investigate the pharmacokinetics of single escalating doses of GSK356278 in healthy male volunteers</outcome>
      <timepoint>72 hours</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  AST, ALT, alkaline phosphate and bilirubin less than or equal to 1.5 times upper limit
             of normal.

          -  Healthy as determined by a responsible and experienced physician based on a medical
             evaluation including medical history, physical examination, laboratory tests and
             cardiac monitoring.

          -  Males aged between 18 and 65 years inclusive at the time of signing the informed
             consent.

          -  Males must agree to appropriate forms of contraception from administration of first
             dose through to 3 months after taking the final dose.

          -  Body weight greater than or equal to 50 kg and BMI within the range of 18-29.9 m2
             (inclusive)

          -  Capable of giving written informed consent.

          -  QTcB or QTcF less than 450 msec</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  A positive pre-study Hep B or positive Hep C result within 3 months of screening.

          -  Current or chronic history of liver disease or known hepatic or biliary abnormalities

          -  A positive pre-study alcohol and drug screen

          -  A positive test for HIV antibody.

          -  History of regular alcohol consumption within 6 months of the study defined as an
             average weekly intake of greater than 21 units or average daily intake of greater than
             3 units

          -  The subject has participated in a clinical trial and has received investigational
             product within the time period of 30 days prior to first dosing day (or 5 half-lives
             or twice the duration of the biological effect of the drug, whichever is longer)

          -  Exposure to more than 4 new chemical entities in the last 12 months prior to the first
             dosing day

          -  Use of prescription or non-prescription drugs including vitamins, herbal and dietary
             supplements within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5
             half-lives (whichever is longer) prior to the first dose unless in the opinion of the
             investigator and medical monitor the medication will not interfere with the study
             procedures or compromise subject safety.

          -  History of sensitivity to any of the study medication or history of drug or other
             allergy that in the opinion of the investigator or medical monitor contraindicates
             their participation.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 ml within a 56 day period.

          -  Unwillingness or inability to follow the procedures in the protocol.

          -  Subject is mentally or legally incapacitated.

          -  Subjects who have asthma or a history of asthma.

          -  Urinary cotinine levels indicative of smoking or history of regular use of tobacco or
             nicotine containing products within 6 months prior to screening.

          -  Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or
             pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior
             to the first dose.

          -  History of any significant psychiatric illness.

          -  Any history of suicidal behaviour or any suicidal ideation of type 4 or 5 on the
             Columbia Suicide Severity Rating Scale in the last 6 months.

          -  History of presence of clinically significant cardiac arrhythmias or other clinically
             significant cardiac disease.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>23/11/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>20</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>7/04/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>GSK Investigational Site - Randwick</hospital>
    <postcode>2031 - Randwick</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the safety, tolerability, and pharmacokinetics of GSK356278 in male
      volunteers</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01031186</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>